Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On December 14, 2021, the Compensation Committee (the "Compensation Committee") of the Board of Directors of ARCA biopharma, Inc. (the "Company") approved the following incentive stock option grants to the executive officers listed below pursuant to the Company's 2020 Equity Incentive Plan (the "2020 Plan"):





                                                        Options
Name and Title                                          Granted (1)
Michael Bristow                                            95,000
President and Chief Executive Officer
Thomas A. Keuer                                            35,000
Chief Operating Officer
Christopher Ozeroff                                        27,500
Senior Vice President, General Counsel & Secretary
C. Jeffrey Dekker                                          17,700
Chief Financial Officer

(1)Exercise price of $2.29 per share, the closing price of the Company's common stock on the Nasdaq Capital Market on December 14, 2021. Each Option vests in 36 equal monthly installments measured from December 14, 2021. In the event of a change in control of the Issuer, 50% of the unvested options shall become fully and immediately vested upon the closing date of such change in control, provided, however, that on the earlier of (i) the one-year anniversary of the closing date or (ii) involuntary termination, any options that remain unvested on such earlier date shall become fully and immediately vested.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses